Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations

Abstract

Nantenine, as well as a number of flexible analogs, were evaluated for acetylcholinesterase (AChE) inhibitory activity in microplate spectrophotometric assays based on Ellman’s method. It was found that the rigid aporphine core of nantenine is an important structural requirement for its anticholinesterase activity. Nantenine showed mixed inhibition kinetics in enzyme assays. Molecular docking experiments suggest that nantenine binds preferentially to the catalytic site of AChE but is also capable of interacting with the peripheral anionic site (PAS) of the enzyme, thus accounting for its mixed inhibition profile. The aporphine core of nantenine may thus be a useful template for the design of novel PAS or dual-site AChE inhibitors. Inhibiting the PAS is desirable for prevention of aggregation of the amyloid peptide Aβ, a major causative factor in the progression of Alzheimer’s disease (AD).

Introduction

Alzheimer’s disease (AD) is an incapacitating condition which afflicts millions of people worldwide. The disease is especially prevalent among the elderly and is associated with severe deficits in cognition and memory [1-3]. In the advanced stages of AD, dramatic changes in the emotional state, psychological well-being and personality are observed [4,5]. The onset and progression of AD is thought to be a consequence of the formation of neuritic plaques via aggregation of the amyloid peptide Aβ (the amyloid hypothesis of AD) [6-10].

Research over the years has supported early hypotheses that a deficit in cholinergic neurotransmission plays a major role in the neurodegeneration associated with the disease [11,12]. Acetylcholinesterase (AChE) is an enzyme which is responsible for the degradation of the neurotransmitter acetylcholine. Most of the current treatments for AD employ compounds which act as inhibitors of acetylcholinesterase and thereby improve cholinergic deficits. Four compounds are commonly prescribed for treatment of AD based on this mechanism of action namely galanthamine (1), tacrine (2), donepezil (3) and rivastigmine (4) (Figure 1) [13,14]. These therapeutics offer short-term improvement in treating symptoms of the disease with modest benefits in slowing the decline in behavior, function and cognition associated with the disease [15-17]. All of the approved AChE inhibitors have potentially serious side-effects especially with long-term use, and more efficacious and safer alternatives are desirable [18-21].

Figure 1.

Clinically available AChE inhibitors.

AChE has two main binding domains, the catalytic site and a peripheral anionic site (PAS) [22,23]. There is evidence that AChE facilitates the formation of amyloid fibrils via a set of amino acids located in the vicinity of the PAS and that molecules which bind to the PAS prevent aggregation of the amyloid peptide Aβ [24,25]. Based on these developments, there has recently emerged a new therapeutic strategy which involves the use of molecules endowed with the ability to bind to the catalytic site and PAS of AChE simultaneously [26-29]. Such dual-acting molecules should be more efficacious in decelerating the progression of the disease via prevention of Aβ accumulation via PAS inhibition as well as providing the usual palliative cognitive and memory improvements associated with the inhibition of the catalytic site of the enzyme.

Aporphines are a family of compounds that are structurally and biogenetically related to isoquinoline alkaloids [30]. A number of aporphines have shown biological activity as dopamine receptor and serotonin receptor ligands and there are reports of some members which have cytotoxic and antimalarial activities [31-39]. Relatively few aporphines have been evaluated as AChE inhibitors. In that regard, a recent report indicated that aporphinoids 5 and 6 (Figure 2) ex Corydalis turtschaninovii Besser (Papaveraceae) show moderate activity with half maximal inhibitory concentration (IC₅₀) values of 27.1 and 48.7 μM respectively [40]. Structurally-related synthetic oxoaporphines and isooxoaporphines have been recently reported to possess anticholinesterase activity, inhibiting the enzyme non-competitively [41]. The aporphine 7 has also been reported to have moderate AChE inhibitory activity (34.5% inhibition at 10⁻⁴ M). The structural similarity between nantenine (8), (an aporphine which we are currently investigating as a 5-HT_2A receptor ligand) and the aforementioned aporphines prompted us to investigate the anticholinesterase activity of 8. We initially compared 8 with the known AChE inhibitor galanthamine (1) in a TLC anticholinesterase bioautographic assay [42] and found that 8 showed activity. To understand the mode of inhibition, enzyme kinetics studies were undertaken. In order to explore the influence of molecular rigidity on AChE inhibitory activity of 8, we have synthesised and evaluated a small library of nantenine congeners. We also performed molecular docking studies on nantenine in order to better understand its mode(s) of binding to the enzyme.

Figure 2.

Structures of known aporphinoid AChE inhibitors (5, 6 and 7) and nantenine (8).

Materials and Methods

Chemistry

General Methods and Instrumentation

High resolution electron impact mass spectra (HREIMS) were obtained using an Agilent 6520 Q-TOF (Santa Clara, CA)instrument. NMR data were collected on a Bruker 500 MHz machine (Billerica, MA) with TMS as internal standard and CDCl₃ (Sigma-Aldrinc Inc., St. Louis, MO) as solvent unless stated otherwise. Chemical shift (δ) values are reported in ppm and coupling constants in Hertz (Hz). Melting points were obtained on a Mel-Temp capillary electrothermal melting point apparatus. Reactions were monitored by TLC (Newark, Delaware, NJ) with Analtech Uniplate silica gel G/UV 254 (1101D, Dubuque, IA) precoated plates (0.2 mm). TLC plates were visualised by UV (254 nm) and by staining with phosphomolybdic acid reagent followed by heating. Flash column chromatography was performed with Silicagel 60 (EMD Chemicals Darmstadt, Germany, 230-400 mesh, 0.04-0.063 μm particle size).

Synthesis

3-(benzo[d][1,3]dioxol-5-yl)-4,5-dimethoxybenzaldehyde (11)

A mixture of Pd(PPh₃)₄ (2.35 g, 2.04 mmol) and commercially available 5-bromoveratraldehyde 10 (5 g, 20.4 mmol) in DME (250 mL) was stirred for 15 min at 20°C under argon. 2M aqueous K₂CO₃ (71.5 mL, 142.8 mmol) was added to the mixture, followed by boronic acid 9 (6.77 g, 40.8 mmol) in DME. The mixture was refluxed for 18 h and then cooled to RT. The reaction mixture was treated with water and ethyl acetate and the layers were separated. The organic extract was washed sequentially with 1M NaOH and water then dried over Na₂SO₄. The solvent was evaporated to give crude 10, which was purified by column chromatography (hexanes:EtOAc, 4:1). Compound 11 (5.66 g, 96%) was obtained as a pale yellow oil: ¹H NMR (500 MHz, CDCl₃): δ 9.92 (s, 1H), 7.44 (d, 1H, J = 2 Hz), 7.42 (d, 1H, J = 2 Hz), 7.06 (d, 1H, J = 1.7 Hz), 7 (dd, 1H, J = 8, 1.7 Hz), 6.89 (d, 1H, J = 8 Hz), 6.02 (s, 2H), 3.97 (s, 3H); 3.71 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 191.2, 153.7, 151.9, 147.5, 147.2, 135.7, 132.3, 130.8, 127.2, 122.7, 109.7, 109.3, 108.3, 101.2, 60.7, 56.1. HREIMS calcd. for C₁₆H₁₄O₅ [M]⁺ 286.0841; found 286.0841.

(E)-5-(2,3-dimethoxy-5-(2-nitrovinyl)phenyl)benzo[d][1,3] dioxole (12)

A mixture of aldehyde 11 (5.31 g, 18.56 mmol), ammonium acetate (1.43 g, 18.56 mmol), nitromethane (4.98 mL, 92.82 mmol), and glacial AcOH was refluxed for 4 h. After cooling to RT, the product was filtered and recrystallised from EtOH to afford 12, as a yellow solid (5.15 g, 84%): mp 124–127°C. 1H NMR (500 MHz, CDCl3): δ 7.97 (d, 1H, J = 13.6 Hz), 7.55 (d, 1H, J = 13.6 Hz), 7.14 (d, 1H, J = 2.1 Hz), 7.02 (d, 1H, J = 1.7 Hz), 7.01 (d, 1H, J = 2.1 Hz), 6.96 (dd, 1H, J = 8, 1.7 Hz), 6.88 (d, 1H, J = 8 Hz), 6.02 (s, 2H), 3.95 (s, 3H); 3.68 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 153, 150.3, 147.8, 147.5, 139.2, 136.6, 136.6. 130.9, 125.9, 125.1, 122.9, 111, 109.9, 108.5, 101.4, 61, 56.3. HREIMS calcd. for C17H16NO6 [M+H]+ 330.0899; found 330.0971.

2-(3-(benzo[d][1,3]dioxol-5-yl)-4,5-dimethoxyphenyl) ethanamine (13)

trimethylsilyl chloride (TMSCl) (5 mL, 24.2 mmol) was added to a vigorously stirred suspension of LiBH₄ (0.35 g, 7.62 mmol) in anhydrous tetrahydrofuran (THF) (15 mL) over a period of 2 min. After the gas evolution had ceased, the trimethylsilane was removed by purging the solution with argon. Then, over a period of 5 min, a solution of 12 (1 g, 3.03 mmol) in anhydrous THF (15 mL) was added and the mixture was heated for 18 h at reflux. After cooling to RT, the mixture was quenched carefully with methanol (25 mL) at 0°C. The solvent was removed with a rotatory evaporator, the resulting residue dissolved in 20% aq KOH (50 mL), and extracted with DCM (3 × 50 mL). The combined extracts were dried (Na₂SO₄) and then concentrated under reduced pressure. This gave 13 as an oil (0.90 g, 99%). ¹H NMR (500 MHz, CDCl₃): δ 7.1 (d, 1H, J = 1.3 Hz), 7.04 (d, 1H, J = 1.5, 8 Hz), 6.88 (d, 1H, J = 8 Hz), 6.77 (s, 1H), 6.76 (s, 1H), 6.02 (s, 2H), 3.92 (s, 3H), 3.62 (s, 3H), 3.01 (t, 2H, J = 7 Hz), 2.75 (t, 2H, J = 7 Hz). ¹³C NMR (125 MHz, CDCl₃): δ 153, 147.3, 146.7, 144.8, 135.7, 135.2, 132.2, 122.6, 122.6, 111.9, 109.9, 108.1, 101, 60.5, 56, 43.5, 40.

N-(3-(benzo[d][1,3]dioxol-5-yl)-4,5-dimethoxyphenethyl) formamide (14a)

Amine 13 (0.46 g, 1.53 mmol), ethyl formate (0.31 mL, 3.9 mmol) and triethylamine (0.43 mL, 3.10 mmol) were heated to reflux for 48 h. Removal of excess ethyl formate and triethylamine under reduced pressure gave a dark-brown oil, that was purified by column chromatography (MeOH:DCM, 1:99). Compound 14a (0.46 g, 90.8%) was obtained as an orange-red oil: ¹H NMR (500 MHz, CDCl₃): δ 8.12 (s, 1H), 7.05 (s, 1H), 6.98 (d, 1H, J = 8 Hz), 6.85 (d, 1H, J = 8 Hz), 6.73 (br. s, 2H), 5.98 (s, 2H), 3.88 (s, 3H), 3.56 (m, 6H), 2.82 (t, 2H, J = 6.9 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 161.4, 153.1, 147.4, 146.8, 135.4, 134.4, 133.6, 131.9, 122.7, 122.6, 111.7, 109.9, 108.2, 101.2, 60.6, 56.1, 39.3, 35.5. HREIMS calcd. for C₁₈H₂₀NO₅ [M+H]⁺ 330.1263; found 330.1333.

N-(3-(benzo[d][1,3]dioxol-5-yl)-4,5-dimethoxyphenethyl) acetamide (14b)

The amine 13 (0.32 g, 1.06 mmol), acetyl chloride (0.12 mL, 5.5 mmol) and triethylamine (0.45 mL, 10 mmol) were mixed with dichloromethane (10 mL) and stirred for 6 hours at 0°C. The reaction was treated with saturated sodium bicarbonate, extracted with DCM (3 × 35 mL), dried over Na₂SO₄ and concentrated under reduced pressure to give a yellow oil, that was subsequently purified by column chromatography (MeOH:DCM, 1:99). Compound 14b (0.33 g, 91%) was obtained as an orange-red oil: ¹H NMR (500 MHz, CDCl₃): δ 8.12 (s, 1H), 7.06 (br. s, 1H), 6.98 (d, 1H, J = 8 Hz), 6.86 (d, 1H, J = 8 Hz), 6.73 (br. s, 1H), 5.98 (s, 2H), 5.71 (br. s, 1H), 3.88 (s, 3H), 3.58 (s, 3H), 3.51 (dd, 2H, J = 13.2, 6.5 Hz), 2.78 (t, 2H, J = 7 Hz), 1.95 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.1, 153.1, 147.4, 146.8, 145, 135.4, 134.7, 131.9, 122.6, 122.5, 111.7, 109.8, 108.1, 101, 60.5, 56, 40.7, 35.6, 23.4. HREIMS calcd. for C₁₉H₂₂NO₅ [M+H]⁺ 344.1415; found 344.1488.

Synthesis of compounds 15a and 15b

To a stirred solution of amide 14a (0.46 g, 1.4 mmol) in acetonitrile (5 mL) was added POCl₃ (0.65 mL, 7 mmol) at RT, and the resulting mixture was heated at 50°C for 12 h. The reaction mixture was concentrated, and the quaternary salt was dissolved in DCM (25 mL). After the mixture was cooled to 0°C, it was diluted with water, made basic with 5% aqueous NH₄OH, and extracted with DCM (3 × 25 mL). The organic solution was washed with water (30 mL), dried with anhydrous Na₂SO₄ and concentrated to give a yellow crude dihydroisoquinoline. Sodium borohydride (1.04 g, 27.6 mmol) was added portion-wise to a stirred solution of the crude dihydroisoquinoline in methanol (20 mL) and the mixture was stirred at 0°C for 3 h. The reaction mixture was concentrated, and excess NaBH₄ was destroyed by adding water and glacial acetic acid until gas evolution ceased. The mixture was extracted with DCM (3 × 25 mL), dried over Na₂SO₄ and concentrated to give orange oil. This crude oily tetrahydroisoquinoline was treated with aqueous formaldehyde solution, (37%, 2.59 mL, 2.55 mmol) in anhydrous DCM (10 mL) and then with NaBH(OAc)₃ (1.35 g, 6.38 mmol). The mixture was allowed to stir at RT for 24 h. The reaction was quenched with 5% aqueous sodium bicarbonate (25 mL), and extracted with ethyl acetate (2 × 25 mL), dried over Na₂SO₄ and concentrated to dryness. The residue was purified via silica flash column chromatography (MeOH:DCM, 2:98) to provide 15a. Similar procedures were used to prepare 15b from 14b.

8-(benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-2-methyl-1,2,3, 4-tetrahydroisoquinoline (15a)

15a was prepared from 14a in 88% overall yield as bright yellow crystals: mp 82–84°C. ¹H NMR (500 MHz, CDCl₃): δ 6.87 (d, 1H, J = 7.9 Hz), 6.70–6.65 (m, 3H), 6.01 (d, 2H, J = 8.4 Hz), 3.88 (s, 3H), 3.54 (s, 3H), 3.15 (br. s, 2H), 2.94 (br. s, 2H), 2.65 (br. s, 2H), 2.35 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 151, 147.3, 146.5, 144.8, 134, 129.8, 129.5, 125.8, 122.6, 111.6, 110, 108.2, 101, 60.8, 56.5, 55.8, 52.6, 46.3, 29.8; HREIMS calcd. for C₁₉H₂₁NO₄ [M]⁺ 327.1478; found 327.1471.

8-(benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline (15b)

Prepared from 14b, as a mixture of isomers, in 90% overall yield as bright yellow crystals: mp 101–104°C. ¹H NMR (500 MHz, CDCl₃): δ 6.87–6.84 (m, 1H), 6.76–6.67 (m, 1H), 6.66–6.65 (m, 2H), 6.03–6 (m, 2H), 3.87 (s, 3H), 3.78–3.71 (m, 1H), 3.53–3.49 (m, 3H), 3.08–3.07 (m, 2H), 2.77–2.71 (m, 2H), 2.38–2.46 (m, 3H), 0.97–0.94 (m, 3H); ¹³C NMR (125 MHz, CDCl₃) (doubling of signals observed; average values for isomeric shifts reported): δ 151, 147.3, 146.5, 145.1, 134.6, 130.8, 129.9, 128.6, 123.3, 112, 110.6, 108.1, 101, 60.8, 55.7, 55, 44.1, 42, 26.3, 16.2; HREIMS calcd. for C₂₀H₂₃NO₄ [M]⁺ 341.1627; found 341.1628.

AChE Inhibition Assays

AChE inhibition was determined using the method of Adsersen et al [43] with ATCI as substrate. In brief, to a 96-well microplate, 25 μL substrate, 15mM ATCI in water, 125 μL 3 mM DTNB in buffer C (50 mM Tris–HCl, pH 8, 0.1M NaCl, 0.02 M MgCl₂·6H₂O), 72.5 μL buffer B (50 mM Tris–HCl, pH 8, 0.1% bovine serum albumin) and 2.5 μL test compound solution dissolved in DMSO were added and the absorbance was measured seven times at 405 nm every 19 s in a PowerWave 200 Microplate Scanning Spectrophotometer (Winooski, VT). Then 25 μL AChE (0.22 U/mL in buffer B) was added to each of the wells and the absorbance was measured again seven times at 405 nm every 19 s. The reaction rate was calculated by the GraphPad Prism software version 5.0 (LaJolla, CA) and Microsoft Excel. Any increase in absorbance due to the spontaneous hydrolysis of substrate was corrected by subtracting the rate of the reaction before adding the enzyme. Percentage inhibition was calculated by comparing the rates for the samples to the blank (2.5 μL DMSO instead of test compound solution). IC₅₀ values were calculated by nonlinear regression analysis using GraphPad Prism. Each experiment was performed in triplicate [43].

Docking studies with Nantenine

The binding of the nantenine and Electrophorus electricus AChE was examined in silico. All docking studies were performed using Internal Coordinate Mechanics (Molsoft ICM version 3.6-1, LaJolla, CA) package. The ICM score considers several free energy terms such as van der Waals, hydrogen bonding, Poisson electrostatic desolvation and entropy. ICM sequence-structure alignment is based on zero end gap global alignment (ZEGA) sequence alignment [44] (Needleman and Wunsch algorithm with zero gap and penalties).

Preparation of Homology Model

Since a high-resolution crystal structure of E. electricus AChE is not available, the homology model for molecular modeling purposes was built based on the X-ray crystal structure of Torpedo californica AChE in complex with bis-(5)-tacrine (PDB code 2CMF) which was obtained from the Protein Data Bank. The tacrine ligand and water molecules present in the pdb file were removed prior to building the model. The sequence of E. electricus AChE was aligned with the sequence of Torpedo californica AChE, and showed 70% identity. For the sequence alignment step, the following parameters were used:

• Alignment Algorithm: ZEGA

• Gap Open: 2.4

• Gap Extension: 0.15

• maxPenalizedGap: 99

This alignment, along with a file containing the atomic coordinates of Torpedo californica AChE, was used as an input to the ICM PRO software package to generate the homology model. For the homology model building step the following parameters were used:

• 3D template: 2CMF

• Max loop length: 100

• Nterm extension: 1

• Cterm extension: 1

• Expand gaps by: 1

After energy-minimising using ICM-PRO, the receptor model was saved and used for docking studies.

Generation of ligands

The 2D structure of nantenine (or analogs 15a, 15b, 16 and 17) was drawn with ChemDraw Ultra version 9.0 (Cambridge, MA) and energy minimised through Chem3D Ultra version 9.0/MOPAC (Cambridge, MA), Job Type: Minimum RMS Gradient of 0.01 kcal/mol and RMS distance of 0.1 Å, and saved as MDL MolFile (*.mol).

Docking using the Molsoft ICM 3.6-1 program [45]

To perform the ICM small molecule docking the following steps were executed according to the program guidelines:

• (1)
  Setup docking project:

  • (i)
    The project name was set.
  • (ii)
    The enzyme (receptor) was setup: (The receptor molecule was entered in the receptor molecule data entry box, the binding sites were identified by clicking on the “identify binding sites” button. In this way potential ligand binding pockets were identified. After the receptor setup was complete, the program displayed the receptor with selected binding site residues highlighted in yellow x-7stick presentation).
  • (iii)
    The binding site was reviewed and adjusted: ICM made a box around the ligand binding site based on the information entered in the receptor setup section. The position of the box encompassed the residues expected to be involved in ligand binding.
  • (iv)
    Receptor maps were made: Energy maps of the environment within the docking box were constructed. Flexibility of the receptor residues was set to 4.0.
• (2)Docking simulation was executed: Interactive docking was used to dock nantenine and the other analogs. The molecules were docked in non-chiral mode. The thoroughness level was set to the maximum value of 10. ICM scores were obtained after this procedure.

Results

Chemistry

Compounds 15a and 15b were prepared as outlined in Scheme 1. Commercially available boronic acid 9 and bromoaldehyde 10 were coupled under Suzuki conditions [46,47] affording the biaryl intermediate (11). A nitro-aldol reaction [48,49] on 11 followed by reduction of the nitrostyrene (12), gave amine 13. Compound 13 was condensed with ethyl formate or with acetyl chloride to give amides 14a and 14b. These amides were then subjected to Bischler-Napieralski [50,51] cyclisation to afford intermediate dihydroisoquino-lines which were immediately reduced with NaBH₄ to give intermediate tetrahydroisoquinoline products (due to instability of the imines). Methylation of the tetrahydroisoquinoline intermediates under reductive-amination conditions then furnished the target seco-ring C derivatives 15a and 15b. Compounds 16 and 17 (Figure 3) were prepared as reported by us elsewhere [52].

Scheme 1.

Synthesis of target analogs 15a-15b. Reagents and conditions: (a) Pd(PPh₃)₄, DME, K₂CO₃, reflux, 24h; (b) CH₃NO₂, NH₄OAc, reflux, 4h; (c) LiBH₄, TMSCI, THF, reflux; (d) HCOOEt, Et₃N, DCM for 14a; (e) acetyl chloride, Et₃N, DCM for 14b; (f) POCl₃, MeCN, 50°C, 12h; (g) NaBH₄, MeOH, 0°C, 4h; (h) HCNO, NaBH(OAc)₃, DCM, rt, 24h.

Figure 3.

Other seco-ring C nantenine analogs.

Enzyme inhibition and kinetics assays

IC₅₀ values for compounds 8, 15a, 15b, 16 and 17 determined with a microplate assay [53] using lyophilised Electrophorus electricus AChE (Type VI, Sigma-Aldrich, MO) and based on Ellman’s method, are summarised in Table 1. The lead compound nantenine, showed the highest inhibitory activity with an IC₅₀ of 1.09 μM. The seco-ring C analogs 15a and 15b were prepared to evaluate whether the rigid aporphine frame-work was required for activity. We were also interested in evaluating these compounds since they are more accessible synthetically, so that any follow-up SAR studies would be facilitated. Both compounds were approximately two-fold less active than nantenine. Compound 16, in which the biaryl bond of nantenine is absent, was 17 times less active than the lead molecule. The flexible analog 17 had the lowest inhibitory activity among the ring-truncated analogs, being inactive (IC₅₀ > 100 μM). Taking together the results obtained from the SAR analysis of this set of compounds, it is apparent that ring C and ring B are required to be intact for anticholinesterase activity. Therefore it appears that the rigid aporphine core of nantenine is an important structural feature for AChE inhibitory activity.

Table 1.

AChE inhibitory activity of analogues.

Compound	IC50 AChE (μM)a
Nantenine (8)	1.09 ± 0.17
15a	2.63 ± 0.38
15b	2.38 ± 0.21
16	18.06 ± 1.92
17	> 100b
Galanthaminec	0.53 ± 0.11

^aResults are the mean of three replications (± SEM of three experiments).

^bConsidered inactive

^cReference compound.

To determine the mode of inhibition exhibited by nantenine, we carried out an evaluation of the steady-state kinetics of the enzyme in the presence of nantenine. A double reciprocal (1/V vs 1/[S], Lineweaver-Burk) plot was performed and this indicated mixed inhibition since lines of increasing gradient showed increasing x-intercepts (Figure 4). Figure 5 shows a Dixon plot which allowed for calculation of the K_i of nantenine in this assay (18.7 μM).

Figure 4.

Lineweaver-Burk steady-state inhibition plot showing mixed inhibition for nantenine.

Figure 5.

Dixon plot. (Intercept on the x-axis is −K_i).

Docking experiments

To further understand the structural basis for the anti-AChE activity seen in 8, molecular docking experiments were performed with the program ICM Pro^® [54]. The crystal structure of Torpedo californica AChE (TcAChE) bound to bis-(5)-tacrine was obtained from the Protein Data Bank (PDB) - PDB code 2CMF. Bis-(5)-tacrine was removed and a homology model was generated for Electrophorus electricus AChE using the homology modeling features of the program. Manipulations were performed to allow for identification of the binding sites in the homology modelled enzyme. After energy-minimisation, nantenine was docked into the identified binding regions of the enzyme. Scoring functions from this docking experiment are reported in Table 2. The known catalytic site inhibitor galanthamine (1) was also docked for comparison. The docking scores suggest that nantenine may bind preferentially to the catalytic site since the three most favorable conformations are located in this site.

Table 2.

ICM docking scores for nantenine (8) and galanthamine (1) in AChE.

Pose numbera	ICM docking scores	Binding site
1	−59.2	Catalytic
2	−55.09	Catalytic
3	−53.9	Catalytic
4	−53.75	PAS
5	−53.56	Catalytic
6	−53.4	Catalytic
7	−52.61	PAS
8	−52.56	PAS
9	−52.31	PAS
10	−51.43	Catalytic
Galanthamine	−59.52b	Catalytic

^aranked in order or increasing energy

^btop score which corresponds to the lowest energy in ICM

Catalytic site interactions of nantenine

Inspection of the top binding pose in the active site indicates that nantenine interacts with the enzyme via π-π stacking interactions between the Trp84 and rings A and D as well as similar interactions between the Tyr330 and ring D. Both of these interactions occur in the anionic sub-site [55] region of the enzyme. Of the three amino acid residues in the catalytic triad [56] (His440, Ser200 and Glu327), nantenine interacts only with Ser 200 (via the hydrophobic contacts with ring B). Nantenine also shows interactions with Gly118 in the oxyanion hole [57] region of AChE. Other hydrophobic interactions help to stabilise the molecule in the active site. Interactions of nantenine in the catalytic site of the enzyme have been displayed with LigPlot [58] (Figure 6) for ease of viewing.

Figure 6.

A is an ICM model of nantenine in the catalytic site of AChE. Pose shown is for lowest energy conformation (pose number 1 in Table 2) and B the LigPlot model of nantenine in the catalytic site of AChE.

PAS interactions of nantenine

The ICM docking experiments also predicted binding poses for nantenine in the PAS. Figure 7 shows a LigPlot model for the key interactions of pose number four which indicates that nantenine is stabilised via a hydrogen-bonding interaction between the C2 oxygen atom and the phenolic group of Tyr70 in the PAS. π-π stacking interactions between the aromatic rings of nantenine and Trp279 as well as between Y334 and ring A also seems to be important for binding to the PAS, based on inspection of our ICM model.

Figure 7.

A is an ICM model of nantenine in the PAS of AChE. Pose shown is for the lowest energy conformation in the PAS (pose number 4 in Table 2) and B is the LigPlot model of Nantenine in the PAS.

The ICM models may be used to explain the mode of inhibition exhibited by nantenine; The mixed mode of inhibition is most likely to be due to nantenine binding to both the catalytic site and PAS.

Docking of 15a, 16 and 17

In order to begin to rationalise the trends in anticho-linesterase activity seen in our analogs, ICM docking simulations were then performed with compounds 15a, 16 and 17. Table 3 summarises results from these docking experiments. The docked poses were evaluated by visual inspection. The three lowest energy poses for compound 15a were all located in the catalytic site.

Table 3.

ICM predicted binding sites for 15a, 16 and 17.

Compound	Pose number	ICM scores	Binding sitea
15a b	1	−60.84	Catalytic
	2	−57.93	Catalytic
	3	−56.9	Catalytic
16 c	1	−69.7	PAS
	2	−68.14	Catalytic
	3	−67.75	PAS/ Catalytic
17	1	−85.27	–
	2	−84.49	–
	3	−84.34	–

^aCatalytic site or PAS

^bTop nine binding poses were in catalytic site, tenth in PAS

^cBinding poses four to ten are in PAS

However, in the case of compound 16, among the top three binding poses, one was in the PAS, one in the catalytic site and the third in both the catalytic site and PAS. Compound 17 did not dock into the catalytic site or the PAS of the enzyme which is consistent with the low activity observed with this compound (Table 1). Visual inspection showed that compound 17 was docked in a region on the outer surface of the enzyme. Therefore, the relatively good ICM score obtained for compound 17 is clearly not due to the active site or PAS inhibition.

Discussion

Alzheimer’s disease (AD) is a neurodegenerative condition, the onset and progression of which is associated with deficits in cholinergic neurotransmission as well as aggregation of the amyloid peptide Aβ [6-10]. A major biological target for the development of anti-AD drugs is the enzyme acetylcholinesterase. Inhibitors of acetylcholinesterase have proved to be of therapeutic value in the treatment of Alzheimer’s disease and have been the front-line approach in this regard [13,14]. This enzyme is known to possess two binding domains: a catalytic site which binds the endogenous neurotransmitter acetylcholine and catalyses its degradation and a peripheral anionic site [22,23]. Clinically available inhibitors have the inhibition of the catalytic site of the enzyme as an integral part of their mode of action. This mode of action of anti-AD drugs is in line with the cholinergic hypothesis of Alzheimer’s disease [59,60]. However, current interest is in the identification and development of molecules which potently inhibit both the catalytic site and peripheral anionic site of the enzyme [27]. Dual-site inhibition of the enzyme is beneficial, since inhibition of the catalytic site results in improvements in cholinergic deficits, while inhibition of the peripheral anionic site prevents aggregation of toxic amyloid peptide Aβ [24,25,61]. A number of chemical scaffolds have been identified which fit this role, some of which utilise a dimeric design for dual AChE inhibition [62-64]. Our work here indicates that the aporphine scaffold may represent another opportunity to develop novel dual-site AChE inhibitors.

A number of analogues of our lead molecule, nantenine were synthesised and evaluated in an Ellman assay for AChE inhibition. These analogs were designed to probe the requirements for structural rigidity of the aporphine core of the lead compound in inhibiting the enzyme. We found that the rigidity of nantenine was an important structural feature for AChE inhibition. Others have found that the less rigid tetrahydroisoqui-noline precursors of some aporphines show higher levels of AChE inhibition than the aporphines [65]. These results together suggest that the structural rigidity of aporphines as a group per se is not the only determinant of enzyme activity, although in the case of nantenine this rigidity does appear to play a significant role. Nantenine showed mixed inhibition kinetics in our enzyme assays. Interestingly, nantenine was previously shown to be inactive in an AChE assay with rat synaptosomal membrane as the enzyme source [66]. The assay conditions or source of the enzyme may account for the discrepancy in both the previous and currently reported results.

Our docking experiments suggest that nantenine is capable of binding to both the catalytic site and the PAS of AChE, which could account for its mixed mode of inhibition. This study is the first to examine the docking of aporphines and the flexible analogs, although there is one recent study where the docking of structurally related oxoaporphines and oxoisoaporphines was reported [67]. Like nantenine, the molecular modelling experiments suggest that the oxoaporphines and oxoisoaporphines interact with the PAS. In the case of the flexible analogs 15a, 16 and 17, we found that visual inspection of the docked ICM poses seems to be a good method for predicting activity or lack thereof in this series of compounds. However, the top three ICM scores for nantenine (8), 15a and 16 did not show good qualitative correlation with the observed inhibitory activities, suggesting that the ICM score is not a good predictor of relative AChE inhibitory activity for this series. This may be due in part to the occurrence of multiple binding modes for these compounds.

In considering the design of novel anti-AD drugs, dual inhibition of AChE is a significant strategy to explore. Nantenine is an interesting lead for such studies. Apart from the dual inhibitory profile, pharmacokinetic factors such as blood-brain barrier penetrability will also be important in the future design of potential anti-AD nantenine analogs. The optimal clogP for blood-brain barrier penetrability is 2–5 [68]. In this regard, nantenine is perhaps a better lead than some other anti-AChE aporphinoids previously identified such as compound 5 [40], which predictably will not cross the blood-brain barrier due to its quaternised nitrogen functionality (clogP of nantenine and 5 = 3.6 and −1.4 respectively as calculated with ChemBioDraw Ultra version 11).

Conclusions

SAR explorations have revealed that the rigid structure of nantenine is important for anticholinesterase activity; increasing molecular flexibility was associated with a decrease in AChE inhibition. Since the inhibition was of the mixed type, it is perceptible that nantenine binds to both the PAS and the catalytic site. This is corroborated by our molecular docking studies which indicated key H-bond and π-π stacking interactions of nantenine in the PAS. The aporphine scaffold of nantenine may be useful for the synthesis of novel PAS or dual-site AChE inhibitors.